0001209191-22-040255.txt : 20220701
0001209191-22-040255.hdr.sgml : 20220701
20220701163701
ACCESSION NUMBER: 0001209191-22-040255
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220701
FILED AS OF DATE: 20220701
DATE AS OF CHANGE: 20220701
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Collard Craig A
CENTRAL INDEX KEY: 0001363558
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37490
FILM NUMBER: 221061975
BUSINESS ADDRESS:
BUSINESS PHONE: 919-678-6611
MAIL ADDRESS:
STREET 1: C/O CORNERSTONE THERAPEUTICS INC.
STREET 2: 1255 CRESCENT GREEN DRIVE, SUITE 250
CITY: CARY
STATE: NC
ZIP: 27518
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Sierra Oncology, Inc.
CENTRAL INDEX KEY: 0001290149
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1820 GATEWAY DRIVE
STREET 2: SUITE 110
CITY: SAN MATEO
STATE: CA
ZIP: 94404
BUSINESS PHONE: (605) 376-8679
MAIL ADDRESS:
STREET 1: 1820 GATEWAY DRIVE
STREET 2: SUITE 110
CITY: SAN MATEO
STATE: CA
ZIP: 94404
FORMER COMPANY:
FORMER CONFORMED NAME: ProNAi Therapeutics Inc
DATE OF NAME CHANGE: 20040513
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-07-01
1
0001290149
Sierra Oncology, Inc.
SRRA
0001363558
Collard Craig A
C/O SIERRA ONCOLOGY, INC.
1820 GATEWAY DR., SUITE 110
SAN MATEO
CA
94404
1
0
0
0
Common Stock
2022-07-01
4
D
0
13500
55.00
D
0
D
Stock Option (right to buy)
13.88
2022-07-01
4
D
0
10000
0.00
D
2030-05-28
Common Stock
10000
0
D
Stock Option (right to buy)
18.11
2022-07-01
4
D
0
6000
0.00
D
2031-06-08
Common Stock
6000
0
D
The option fully vested on May 28, 2021.
Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price.
The option fully vested on June 8, 2022.
/s/ Craig A. Collard; By: Mary Christina Thomson, Attorney-In-Fact
2022-07-01